Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Karolinska Institute

Status: Completed

Conditions: Thromboembolic Events; Covid-19; Bleeding

Treatments: Drug: Dose of Tinzaparin or Dalteparin

Study type: Observational

Funder types: Other

Identifiers

NCT04412304

Anticoagulant therapy Covid-19

Details and patient eligibility

About

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Enrollment: 166 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• laboratory confirmed positive test for SARS-CoV-2
• admitted to ICU because of critical illness due to covid-19

Exclusion criteria

• patients with treatment for thromboembolic complications at arrival to the ICU
• short ICU length of stay defined as discharged the same or the following day as ICU admission

Trial design

166 participants in 3 patient groups

thrombose prophylaxis

Description:

The dose used to prevent thromboembolic complication in critically ill

Treatment:

Drug: Dose of Tinzaparin or Dalteparin

double thrombose prophylaxis

Description:

Double the dose used to prevent thromboembolic complication in critically ill

Treatment:

Drug: Dose of Tinzaparin or Dalteparin

full dose anticoagulant

Description:

Dose used to treat thromboembolic event

Treatment:

Drug: Dose of Tinzaparin or Dalteparin